CN105381451B - 利用可溶性cd24治疗类风湿性关节炎的方法 - Google Patents

利用可溶性cd24治疗类风湿性关节炎的方法 Download PDF

Info

Publication number
CN105381451B
CN105381451B CN201510683408.8A CN201510683408A CN105381451B CN 105381451 B CN105381451 B CN 105381451B CN 201510683408 A CN201510683408 A CN 201510683408A CN 105381451 B CN105381451 B CN 105381451B
Authority
CN
China
Prior art keywords
hours
protein
minutes
fused
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201510683408.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105381451A (zh
Inventor
X.郑
W.吴
Y.刘
P.郑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoimmune Inc
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of CN105381451A publication Critical patent/CN105381451A/zh
Application granted granted Critical
Publication of CN105381451B publication Critical patent/CN105381451B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201510683408.8A 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法 Expired - Fee Related CN105381451B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32907810P 2010-04-28 2010-04-28
US61/329,078 2010-04-28
CN201180021423.6A CN102869369B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180021423.6A Division CN102869369B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法

Publications (2)

Publication Number Publication Date
CN105381451A CN105381451A (zh) 2016-03-09
CN105381451B true CN105381451B (zh) 2021-03-09

Family

ID=44903987

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510683408.8A Expired - Fee Related CN105381451B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法
CN201180021423.6A Expired - Fee Related CN102869369B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180021423.6A Expired - Fee Related CN102869369B (zh) 2010-04-28 2011-04-28 利用可溶性cd24治疗类风湿性关节炎的方法

Country Status (17)

Country Link
US (1) US8808697B2 (https=)
EP (3) EP2563385B1 (https=)
JP (5) JP5899206B2 (https=)
KR (1) KR20130086126A (https=)
CN (2) CN105381451B (https=)
AU (1) AU2011248540B2 (https=)
CA (1) CA2795823C (https=)
DK (1) DK2563385T3 (https=)
EA (2) EA036805B8 (https=)
ES (2) ES2645262T3 (https=)
IL (1) IL222739A0 (https=)
NO (1) NO2563385T3 (https=)
NZ (1) NZ603196A (https=)
PL (2) PL2563385T3 (https=)
PT (2) PT3260128T (https=)
SG (1) SG184907A1 (https=)
WO (1) WO2011139820A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
HRP20201651T1 (hr) * 2015-05-07 2020-12-25 Oncoimmune, Inc. Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola
EP3411062B1 (en) * 2016-02-02 2020-11-25 Oncoimmune Inc. Use of cd24 proteins for treating leptin-deficient conditions
US10758574B2 (en) 2016-04-28 2020-09-01 The Board Of Trustees Of The Leland Stanford Junior University Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy
KR101789449B1 (ko) * 2016-12-08 2017-10-23 박문수 폐유지를 이용한 지방산 메틸에스테르 제조방법
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
EP3624838B1 (en) * 2017-05-15 2023-01-25 Oncoimmune, Inc. Methods of use of soluble cd24 for neuroprotection and remyelination
CN110799206A (zh) * 2017-05-22 2020-02-14 肿瘤免疫股份有限公司 使用可溶性cd24治疗癌症疗法中免疫相关不良事件的方法
CN112543643A (zh) * 2018-03-05 2021-03-23 肿瘤免疫股份有限公司 使用可溶性cd24用于治疗获得性免疫缺陷综合征（hiv/aids）的方法
AU2019269361C1 (en) * 2018-05-14 2025-06-12 Children's Research Institute, Children's National Medical Center Anti-CD24 compositions and uses thereof
MA52811A (fr) * 2018-06-04 2022-03-16 Oncoimmune Inc Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
JP7728747B2 (ja) * 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
CN117279618A (zh) * 2020-11-30 2023-12-22 弗莱德哈钦森癌症中心 用于靶标分子的选择性耗竭的组合物和方法
EP4408862A4 (en) * 2021-09-28 2025-11-12 Acroimmune Guangzhou Biotech Ltd Fusion proteins including the O71 core peptide and their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
CN101254302B (zh) * 1999-05-07 2011-05-11 杰南技术公司 使用与b细胞表面标志结合的拮抗剂治疗自身免疫病
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
US20030106084A1 (en) * 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
CN100522242C (zh) * 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
BR0211091A (pt) * 2001-07-13 2004-06-15 Merck Patent Gmbh Métodos para redução de imunogenicidade de polipeptìdeos
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
EP1613350B1 (en) * 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
AU2007242919B8 (en) * 2003-04-09 2011-11-10 F. Hoffmann-La Roche Ag Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
EP1706507A4 (en) * 2003-11-26 2008-02-20 Univ Ohio State Res Found THE RISK AND PROGRESSION OF MULTIPLE SCLEROSIS PREDICTING POLYMORPHS CD24 GENOTYPES
JP2008507591A (ja) * 2004-05-21 2008-03-13 ゼンコー・インコーポレイテッド 免疫原性が改変されたＣ１ｑファミリーメンバータンパク質
WO2006053245A2 (en) * 2004-11-12 2006-05-18 Iogenetics, Llc Retroviral vectors with introns

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
US20050214290A1 (en) * 2001-03-29 2005-09-29 Yang Liu Methods of blocking tissue destruction by autoreactive T cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
investigating the role of CD24 gene polymorphisms in rheumatoid arthritis;E Sanchez等;《Ann Rheum Dis》;20080831;1197-1198 *

Also Published As

Publication number Publication date
HK1222554A1 (zh) 2017-07-07
EP2563385B1 (en) 2017-08-02
US8808697B2 (en) 2014-08-19
CN102869369B (zh) 2016-05-18
JP2015187162A (ja) 2015-10-29
PT2563385T (pt) 2017-11-10
JP6526872B2 (ja) 2019-06-05
ES2645262T3 (es) 2017-12-04
JP5899206B2 (ja) 2016-04-06
HK1176007A1 (zh) 2013-07-19
EP2563385A1 (en) 2013-03-06
NZ603196A (en) 2014-07-25
EA201790538A2 (ru) 2017-07-31
EA036805B1 (ru) 2020-12-23
CA2795823A1 (en) 2011-11-10
CN102869369A (zh) 2013-01-09
EA201790538A3 (ru) 2017-11-30
EP3845238A1 (en) 2021-07-07
KR20130086126A (ko) 2013-07-31
PL3260128T3 (pl) 2021-02-08
PT3260128T (pt) 2020-10-22
EA027735B1 (ru) 2017-08-31
DK2563385T3 (da) 2017-11-06
CN105381451A (zh) 2016-03-09
JP2017057216A (ja) 2017-03-23
WO2011139820A8 (en) 2013-02-07
EP3260128B1 (en) 2020-07-29
JP6888221B2 (ja) 2021-06-16
JP2018127493A (ja) 2018-08-16
EP3260128A1 (en) 2017-12-27
JP6062502B2 (ja) 2017-01-18
EA201290961A1 (ru) 2013-04-30
IL222739A0 (en) 2012-12-31
PL2563385T3 (pl) 2018-04-30
WO2011139820A1 (en) 2011-11-10
AU2011248540B2 (en) 2014-11-20
JP2013527168A (ja) 2013-06-27
CA2795823C (en) 2019-06-04
JP2019151655A (ja) 2019-09-12
US20130136739A1 (en) 2013-05-30
NO2563385T3 (https=) 2017-12-30
EA036805B8 (ru) 2021-02-25
EP2563385A4 (en) 2013-10-02
ES2826445T3 (es) 2021-05-18
SG184907A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
CN105381451B (zh) 利用可溶性cd24治疗类风湿性关节炎的方法
US10793617B2 (en) Methods of use of soluble CD24 for therapy of rheumatoid arthritis
AU2011248540A1 (en) Methods of use of soluble CD24 for therapy of rheumatoid arthritis
US11547741B2 (en) Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
HK1176007B (en) Methods of use of soluble cd24 for therapy of rheumatoid arthritis
HK1222554B (zh) 利用可溶性cd24治疗类风湿性关节炎的方法
HK40024980A (en) Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222554

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210309

CF01 Termination of patent right due to non-payment of annual fee